Budesonide MMX 9 mg for 8 Weeks: Dosing and Tapering
Yes, budesonide MMX 9 mg should be given once daily for 8 weeks, and tapering is NOT required after this induction course.
Dosing Regimen
The standard induction regimen is straightforward:
- Dose: 9 mg once daily in the morning
- Duration: Up to 8 weeks
- Administration: Swallow whole (do not chew, crush, or break)
- Food: Can be taken with or without food
This dosing is supported by multiple high-quality guidelines 1 and FDA labeling 2, with strong evidence from randomized controlled trials 3, 4, 5.
Tapering: Not Required
The key distinction between budesonide MMX and traditional corticosteroids is that budesonide MMX does NOT require tapering after an 8-week induction course. This is fundamentally different from systemic corticosteroids like prednisolone, which require gradual dose reduction.
The British Society of Gastroenterology guidelines specifically address this for ileal-release budesonide (used in Crohn's disease), stating: "When remission has been achieved, budesonide should be tapered over 1–2 weeks" 1. However, this recommendation applies to the ileal-release formulation used in Crohn's disease, not budesonide MMX used in ulcerative colitis.
For budesonide MMX in ulcerative colitis, the FDA label and clinical trials demonstrate that the medication can be stopped abruptly after 8 weeks without a taper 2. The drug's low systemic bioavailability due to extensive first-pass hepatic metabolism (approximately 90%) means it has minimal hypothalamic-pituitary-adrenal (HPA) axis suppression, eliminating the need for tapering.
Clinical Evidence Supporting No Taper
The pivotal CORE I and CORE II trials 3, 4 and their pooled analysis 5 used budesonide MMX 9 mg for exactly 8 weeks and then stopped abruptly. No tapering protocol was employed, and no adverse events related to abrupt discontinuation were reported. In fact, glucocorticoid-related effects were similar between budesonide MMX and placebo groups 2.
Important Caveats
Duration limitation: Budesonide MMX is approved only for induction therapy, not maintenance. The 2019 AGA guidelines explicitly state that budesonide is "unsuitable for maintenance therapy given the potential for corticosteroid-related adverse effects" 6. If patients require ongoing treatment beyond 8 weeks, transition to appropriate maintenance therapy (5-ASA, immunomodulators, or biologics) should be initiated rather than continuing budesonide.
Disease context matters: The evidence base for budesonide MMX is specifically for mild-to-moderate ulcerative colitis, particularly left-sided disease 7. Subgroup analyses showed the benefit is confined to left-sided disease and not extensive colitis 7.
Response assessment: The most recent 2025 BSG guidelines recommend early assessment (at 2 weeks) of clinical and/or biomarker response to encourage timely escalation if needed 8. Don't wait the full 8 weeks if the patient is clearly not responding.
Avoid prolonged use: Extended treatment beyond 8 weeks increases the risk of systemic corticosteroid effects. One study evaluated up to 16 weeks cumulative exposure and found similar adverse event rates 2, but this should not be routine practice.